In this work, we show how human brain organoids can model lipid abnormalities in ALD. This collaborative study, we combined our expertise in stem cell technology and the lipidomics knowledge from our team. Using human induced pluripotent stem cell (iPSC)-derived brain and spinal cord organoids, miniature 3D brain tissue models grown in the laboratory, we tracked how fat molecule composition changes during brain development over 200 days.[Click to read more ▼]
The research revealed that ALD organoids display early and persistent accumulation of very long-chain fatty acids (VLCFAs), the hallmark of ALD. Remarkably, the lipid alterations observed in these laboratory-grown models closely mirror those found in actual ALD patient brain tissue, validating organoids as relevant models for studying disease mechanisms.
This work demonstrates the power of combining cutting-edge stem cell technology with advanced lipidomics analysis. By creating “mini-brains” from patient cells, we can now study how ALD develops at the molecular level in human tissue—something that would be impossible to do in living patients. These findings open new avenues for understanding early disease processes and testing potential treatments in a controlled, human-relevant system.
Read the full paper